Fertility Institute of Hawaii becomes First Fertility Clinic in Hawaii to Adopt INVOcell

HONOLULU and MEDFORD, Mass., April 3, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that the Fertility Institute of Hawaii, located in Honolulu, is the first clinic in Hawaii to add INVOcell to its scope of reproductive treatments with the addition of INVOcell.

Dr. John Frattarelli, M.D., founder of the Fertility Institute of Hawaii, commented, "INVOcell is a welcomed addition to our palette of services. It provides an additional option for our patients to create the loving families they so desire. The cost of in-vitro fertilization (IVF) and other fertility treatments can add an additional burden to a process that is very stressful in and of itself. We believe it is important to provide this innovative, and cost-effective, approach to achieving pregnancies where other methods have not achieved the desired results.  INVOcell may very well open the door to pregnancy to many couples that otherwise may have given up hope. We are excited with the future possibilities."

Dr. Anatte Karmon, M.D., the Clinical and Research Director at the Fertility Institute of Hawaii, attended the INVOcell training program held on March 24^th, 2018. Dr. Karmon commented, "I was impressed by the simplicity and success rate of the INVOcell model. We are a comprehensive fertility treatment center and take pride in offering all traditional and cutting-edge services to our patients. We are thrilled to announce that INVOcell will now be available to our patients and will provide a cost-effective approach to family building."

INVOcell has the ability to significantly transform the way in which doctors assist infertile patients to become pregnant in a simpler, more natural and cost-effective manner. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. The simplistic INVO can be easily performed in an appropriately trained physician's office without the need for expensive overhead.

About Fertility Institute of Hawaii
Founded in 2010 by Dr. John Frattarelli, M.D., HCLD, the Fertility Institute of Hawaii is the premier fertility clinic in the state of Hawaii, offering superior success rates. The goal of the state-of-the-art center is to provide a private, intimate experience, where the patient is never a number, but an individual who is treated with compassion and concern. Offering world-class technologies and novel treatments, the Fertility Institute of Hawaii has been the clinic of choice for those seeking fertility treatments. Abreast of the latest national and international research and treatment options in fertility management, patients can be assured that they will be provided with a comprehensive individualized treatment plan.

About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology ("ART"). The INVOcell is the first Intravaginal Culture ("IVC") system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization ("IVF") and Intrauterine Insemination ("IUI"). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.

Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
[email protected]

SOURCE INVO Bioscience, Inc.

Related Links

http://www.invobioscience.com